Secondary prevention with calcium channel-blocking drugs in patients after myocardial infarction: a critical review.
The rationale for evaluating the efficacy and safety of calcium entry-blocking drugs to prevent secondary complications in patients after myocardial infarction is presented. The data currently available from postinfarction trials involving verapamil, nifedipine, and diltiazem are critically reviewed, and a comparison of the findings from three major trials of calcium entry-blocking drugs is provided.
D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004110:Diltiazem / Q000627:therapeutic use; D006801:Humans; D009203:Myocardial Infarction / Q000150:complications / Q000517:prevention & control*; D009543:Nifedipine / Q000627:therapeutic use; D012008:Recurrence; D014700:Verapamil / Q000627:therapeutic use
D002121:Calcium Channel Blockers; D014700:Verapamil; D004110:Diltiazem; D009543:Nifedipine